13 - Diabetes Mellitus Flashcards
Prevalence of T1D
10%
What is t1d
chronic autoimmune disease,
T-cell mediated disruption of pancreatic B cells within islets of Langerhans –> causes insulin deficiency
Evidence of immune mediated disease in T2D
Infiltration of pancreas islets by mononuclear cells (insulitis)
• T lymphocytes, monocytes etc.
90 percent with autoantibodies against islets
Immunosuppression –> delayed B cell disruption
t2d prevalence
85-90%
T2D genetics
gkrp
pparg
Risk factors t2d
Obesity
family history
ethnicity
age
Causes of abnormal insulin action (resistance)
Obesity
Hyperinsulinaemia
Adipokines
Lipoglucotoxicity
How can obesity cause t2d
Lipids, metabolites + FFA
= Chronic inflammation affecting adipocytes –> altered adipokine levels –> resistance –> hyperinsulinaemia
How does hyperinsulinaemia cause t2d
Obesity - cells dont respond to insulin
pancreas increases insulin levels –> increases lipid synthesis –> exacerbates
How does Adipokine alter pathway of insulin
Normally, insulin causes the phosphorylation of tyrosine via IRS which activates PI3K and Akt. In resistance, Threonine and serine phosphorylated instead. No activation of Akt so no downstream activation.
Why do fat pregnant ppls not have t2diabetes
Compensation of b cells
- increase in size and no
- increase in function
Why do beta cells decrease in t2d
Genetic factors make some b cells more susceptible to dysfunction
What is lipoglucotoxicity
Excess lipids/glucose in blood –> damage Beta cells –> even less insulin
Treatment for T2D
Biguanides - Metformin Sulfonylureas TZD DDP-4 inhibitors SGLT2 inhibitors
MoA of metformin
• Increases AMPK activation
1) improve insulin receptor function
2) improved glucose transport (GLUT 4)
3) reduce F.A synthesis
4) reduce hepatic gluconeogenesis via inhibiting cAMP activation
5) Increases GLP-1
MoA of sulfonylureas
Closes the K+ channel –> depolarisation –>increased Ca2+ –> insulin secretion.
MoA of thiazolidinediones
• Affects PPARG which is a transcription factor, so it activates genes that increase glucose uptake, decrease gluconeogenesis
DDP-4 inhibitors
sitagliptin- DDP4 breaks down GLP-1 normally and GLP-1 reduces glucagon secretion
SGLT2 inhibitors
target kidney reabsorption of glucose
What is MODY
maturity onset diabetes of the young
What is LADA
latent autoimmune diabetes in adults)
In between the two different types of diabetes m.
Autoantibodies present
Type 3c diabetes
Malfunction in pancreas due to other disease
Diagnostic plasma glucose
Random >11.1
Fasting >7
- Two fasting venous plasma glucose samples needed in asymptomatic
Symptoms of diabetes t2
1) thirst, 2) increased urination 3) weight loss 4) drowsiness 5) coma 6) recurrent infections